CML
News
Starting all CML patients on imatinib could cut costs, team says
Photo courtesy of the CDC New research suggests that starting all patients with chronic myeloid leukemia (CML) on the generic form of Gleevec,...
News
Germline mutations linked to hematologic malignancies
A new study suggests mutations in the gene DDX41 occur in families where hematologic malignancies are common. Previous research showed that both...
News
Ponatinib effective in chronic phase CML regardless of baseline mutation status
Key clinical point: Baseline mutation status had little impact on ponatinib response, and no single or compound mutation was a major driver of...
News
Pinpointing the cells that cause CML relapse
Image by Difu Wu Preclinical research suggests chronic myeloid leukemia (CML) patients have a heterogeneous population of long-term hematopoietic...
News
Novel test detects low levels of residual CML
Key clinical point: A novel test may predict which CML patients in remission can safely stop TKI therapy. Major finding: Digital PCR for BCR-ABL1...
News
New assay detects persistent CML better, team says
A new assay is more accurate than the current gold standard for detecting residual disease in patients with chronic myeloid leukemia (CML),...
News
Generic imatinib launched with savings program
Photo by Rhoda Baer Sun Pharma has announced the US launch of imatinib mesylate tablets, which are a generic version of Novartis’s Gleevec, for...
News
KIR2DL5B genotype predicts outcome in chronic phase–CML
Key clinical point: The presence of KIR2DL5B was associated with worse outcomes in patients with chronic phase–chronic myeloid leukemia treated...
News
Cardiovascular risk assessment required with use of TKIs for CML
Key clinical point: Most patients with chronic myeloid leukemia require long-term tyrosine kinase inhibitor (TKI) therapy, and cardiovascular...
Conference Coverage
Potential new alternative in CML when TKI therapy fails
ASH Annual Meeting Photo courtesy of ASH ORLANDO, FL—ABL001, an allosteric inhibitor of BCR-ABL1, has shown early evidence of single-agent...
Conference Coverage
Chemo quadruples risk for myeloid cancers
Key clinical point: This study quantifies the risks for treatment-related myeloid cancers after chemotherapy. Major finding: Chemotherapy is...